A Novel ANG-BSA/BCNU/ICG MNPs Integrated for Targeting Therapy of Glioblastoma

A Novel ANG-BSA/BCNU/ICG MNPs Integrated for Targeting Therapy of Glioblastoma

Purpose Develop an albumin nanoparticle-based nanoprobe for targeted glioblastoma (GBM) diagnosis and treatment, utilizing Angopep-2 for low-density lipoprotein receptor-related protein (LRP) targeting. Methods Combined albumin-coated superparamagnetic iron oxide (SPIO), Carmustine (BCNU), and indoc...

Full description

Saved in:
Bibliographic Details
Main Authors: Li-Hong Liu BS, Yu-Feng Liu MD, Hong-Bo Zhang MD, PhD, Xiao-Lei Liu BS, Han-Wen Zhang MD, PhD, Biao Huang MD, PhD, Fan Lin MD, PhD, Wei-Hua Li MD, PhD
Format: Article
Language:English
Published: SAGE Publishing 2024-10-01
Series:Technology in Cancer Research & Treatment
Online Access:https://doi.org/10.1177/15330338241281321
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose Develop an albumin nanoparticle-based nanoprobe for targeted glioblastoma (GBM) diagnosis and treatment, utilizing Angopep-2 for low-density lipoprotein receptor-related protein (LRP) targeting. Methods Combined albumin-coated superparamagnetic iron oxide (SPIO), Carmustine (BCNU), and indocyanine green (ICG). Assessed morphology, size, Zeta potential, fluorescence, and drug encapsulation. Conducted in vitro fluorescence/MRI imaging and cell viability assays, and in vivo nanoprobe accumulation evaluation in brain tumors. Results ANG-BSA/BCNU/ICG MNPs exhibited superior targeting and cytotoxicity against GBM cells in vitro. In vivo, enhanced brain tumor accumulation during imaging was observed. Conclusion This targeted imaging and drug delivery system holds promise for efficient GBM therapy and intraoperative localization, addressing Blood-brain barrier (BBB) limitations with precise drug delivery and imaging capabilities.
ISSN:1533-0338

Similar Items